Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.
If you have Type 2 Diabetes and are at risk for heart problems, ask your doctor about GLP-1 medications like semaglutide or liraglutide. These drugs not only help control blood sugar but have been proven to significantly lower your risk of heart attack, stroke, and death. Newer oral versions are available if you dislike injections.
StrongSupportsHIGH confidence
The 3p-MACE associated with GLP1-RAs was reduced by 12% in a meta-analysis of the seven largest trials... There was no heterogeneity between patient subgroups... Due to lower rates of CV death (12%), fatal or nonfatal stroke (16%), and fatal or nonfatal MI (9%), this observation was made. Additionally, there was a decrease in hHF (9%), as well as all-cause mortality (12%), primarily due to albiglutide.
Why this rating
Based on a meta-analysis of seven large, landmark randomized controlled trials (CVOTs).
Source
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Rekha Krishnan et al. · International Journal of Health Sciences and Research · 2023
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →